Kovaltry

Octocog Alfa, the active ingredient in Kovaltry, is a recombinant factor VIII presented as a sterile solution for intravenous use. It replaces the deficient clotting factor in patients with hemophilia A, helping to restore the intrinsic pathway of coagulation and control bleeding episodes.

GNH USA supplies Kovaltry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kovaltry is a recombinant factor VIII used to manage disorders of the intrinsic coagulation pathway, primarily hemophilia A.

- Hemophilia A (congenital factor VIII deficiency): provides prophylactic protection against spontaneous and traumatic bleeding. - Surgical prophylaxis in hemophilia A patients: ensures adequate factor levels to minimise intra‑operative blood loss. - On‑demand treatment of bleeding episodes in hemophilia A: rapidly restores clotting activity to stop active bleeds.

Kovaltry may be associated with a range of adverse reactions following intravenous infusion.

Common Side Effects: - Infusion‑related reactions (e.g., chills, flushing) - Headache - Fever or chills - Nausea - Arthralgia or joint discomfort - Fatigue or malaise

Serious or Rare Side Effects: - Development of inhibitory antibodies against factor VIII - Anaphylactic or severe allergic reactions - Thrombotic events (e.g., deep‑vein thrombosis) - Severe hemolysis - Acute renal impairment - Disseminated intravascular coagulation (rare).

When using Kovaltry, clinicians should observe several safety measures.

- Individualized dosing: adjust based on patient’s factor VIII activity and clinical response. - Inhibitor monitoring: regularly test for anti‑factor VIII antibodies, especially after repeated exposure. - Allergy caution: avoid in patients with known hypersensitivity to any component of the product. - Surgical planning: ensure adequate factor levels are achieved before any invasive procedure. - Concomitant therapy: assess risk when used with other hemostatic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kovaltry can interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates: may increase risk of inhibitor development. - Immune tolerance induction therapy: can alter the efficacy of Kovaltry.

Moderate Interactions (Monitor Closely): - Antifibrinolytic agents (e.g., tranexamic acid): may enhance clot stability, requiring careful monitoring. - Live vaccines: immune response may be affected; schedule vaccinations appropriately. - Immunosuppressive drugs: may modify inhibitor formation risk.